Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Inclusion Criteria:

• Have previously untreated and pathologically confirmed resectable Stage II, IIIA, orIIIB (N2) NSCLC.

• If male, must agree to use contraception or practice abstinence as well as refrainfrom donating sperm during the treatment period and for the time needed to eliminateeach study intervention after the last dose of study intervention.

• If female, may participate if not pregnant or breastfeeding, and at least one of thefollowing conditions apply: 1) not a woman of childbearing potential (WOCBP); or 2)a WOCBP who agrees to follow contraceptive guidance during the treatment period andfor the time needed to eliminate each study intervention after the last dose ofstudy intervention and agrees not to donate eggs (ova, oocytes) to others orfreeze/store for her own use for the purpose of reproduction during this period.

• Have available formalin-fixed paraffin embedded (FFPE) tumor tissue sample blocksfor submission. If blocks are not available, have unstained slides for submissionfor central programmed death-ligand 1 (PD-L1) testing.

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1within 10 days of randomization.

• Have adequate organ function.

Exclusion Criteria:

• Has one of the following tumor locations/types:1) NSCLC involving the superiorsulcus; 2) Large cell neuro-endocrine cancer (LCNEC); or 3) Sarcomatoid tumor.

• Has a history of (non-infectious) pneumonitis /interstitial lung disease thatrequired steroids or has current pneumonitis/interstitial lung disease that requiressteroids.

• Has an active infection requiring systemic therapy.

• Has had an allogenic tissue/sold organ transplant.

• Has a known severe hypersensitivity (≥ Grade 3) to pembrolizumab, its activesubstance and/or any of its excipients.

• Has a known severe hypersensitivity (≥ Grade 3) to any of the study chemotherapyagents and/or to any of their excipients.

• Has an active autoimmune disease that has required systemic treatment in past 2years.

• Has a known history of human immunodeficiency virus (HIV) infection.

• Has a known history of Hepatitis B or Hepatitis C.

• Has a known history of active tuberculosis.

• Has a history or current evidence of any condition, therapy, or laboratoryabnormality that might confound the results of the trial, interfere with theparticipant's participation for the full duration of the trial, or is not in thebest interest of the participant to participate.

• Has known psychiatric or substance abuse disorders that would interfere withcooperating with the requirements of the trial.

• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent orwith an agent directed to another co-inhibitory T-cell receptor.

• Has received prior systemic anti-cancer therapy including investigational agents forthe current malignancy prior to randomization/allocation.

• Has received prior radiotherapy within 2 weeks of start of trial treatment.

• Has received a live vaccine within 30 days prior to the first dose of trial drug.

• Is currently participating in or has participated in a trial of an investigationalagent or has used an investigational device within 4 weeks prior to the first doseof trial treatment.

• Has a diagnosis of immunodeficiency or is receiving either systemic steroid therapyor any other form of immunosuppressive therapy within 7 days prior the first dose oftrial drug.

• Has a known additional malignancy that is progressing or requires active treatmentwithin the past 5 years.